Ephedra
This article was originally published in The Tan Sheet
Executive Summary
Separate letter in same issue of NEJM from Ephedra Education Council consultant Grover Hutchins, MD, charges Christine Haller, MD, and Neal Benowitz, MD, ignored subjects' preexisting conditions when conducting their review of ephedra AEs. Authors reply ephedra still is "unreasonably dangerous" since it can lead to severe health problems in vulnerable populations, especially among those unaware of their underlying condition
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning